Focused On-demand Library for Centromere protein J

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9HC77

UPID:

CENPJ_HUMAN

Alternative names:

Centrosomal P4.1-associated protein; LAG-3-associated protein; LYST-interacting protein 1

Alternative UPACC:

Q9HC77; Q2KHM6; Q5JPD5; Q5T6R5; Q96KS5; Q9C067

Background:

Centromere protein J, also known as Centrosomal P4.1-associated protein, plays a pivotal role in cell division and centrosome function. It is crucial for centriole duplication, inhibiting microtubule nucleation from the centrosome, and regulating the growth of centriolar microtubules. This protein stabilizes centriolar microtubules, inhibits their polymerization, and is essential for centriole elongation and amplification.

Therapeutic significance:

Centromere protein J is linked to Microcephaly 6, primary, autosomal recessive, and Seckel syndrome 4, both of which involve significant neurological deficits and developmental issues. Understanding the role of Centromere protein J could open doors to potential therapeutic strategies for these conditions.